FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Genovese

Research Profile

Disorders

Rheumatoid Arthritis

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Synovial Fluid

Co-author Network

Publications

TOP 3
Mark C Genovese; Sophie Hugot; Takashi Ikawa; Herbert Kellner; Sang-Heon Lee; Vadim Mazurov; Jacob A Aelion; Christine E Codding; Eva Dokoupilova; Patrick Durez; Hanno B Richards; Jerzy Supronik; Shephard Mpofu
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Peter Nash; Sauithree Nayiager; Kurt Oelke; William Palmer; Cristian Rodriguez; Ingrid Delaet; Ayanbola Elegbe; Mark C Genovese; Alan J Kivitz; Charles Ludivico; Michael Corbo
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study.
Michael E Weinblatt; Theresa K Musser; Mark C Genovese; Elliott B Grossbard; David A Jones; Arthur Kavanaugh; Daniel B Magilavy
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Genovese (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mark C Genovese; Sophie Hugot; Takashi Ikawa; Herbert Kellner; Sang-Heon Lee; Vadim Mazurov; Jacob A Aelion; Christine E Codding; Eva Dokoupilova; Patrick Durez; Hanno B Richards; Jerzy Supronik; Shephard Mpofu
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Annals of the rheumatic diseases 2013;72(6):863-9.
2013: Peter Nash; Sauithree Nayiager; Kurt Oelke; William Palmer; Cristian Rodriguez; Ingrid Delaet; Ayanbola Elegbe; Mark C Genovese; Alan J Kivitz; Charles Ludivico; Michael Corbo
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study.
Arthritis care & research 2013;65(5):718-28.
2013: Michael E Weinblatt; Theresa K Musser; Mark C Genovese; Elliott B Grossbard; David A Jones; Arthur Kavanaugh; Daniel B Magilavy
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
The Journal of rheumatology 2013;40(4):369-78.
2013: Mark C Genovese; L Georgescu; G Mirea; E Mociran; I M Biagini; S Bojin; D Cristei; J Sloan-Lancaster
Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
Arthritis and rheumatism 2013;65(4):880-9.
2013: Muhammad U Jawad; Hua Z Ke; Ting Ma; Pei-Gen Ren; Philip Babij; Kate E Fritton; Stuart B Goodman; Mark C Genovese
Effects of sclerostin antibody on healing of a non-critical size femoral bone defect.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2013;31(1):155-63.
2012: Mark C Genovese; Manuela Le Bars; Michael Luggen; Michael Schiff; Richard Aranda; Ayanbola Elegbe; Maxime Dougados
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
The Journal of rheumatology 2012;39(8):1546-54.
2012: Mark C Genovese; Chenglong Han; Elizabeth C Hsia; Edward C Keystone; Frederick T Murphy; Shreekant Parasuraman; Jacqueline Buchanan; Timothy Gathany; Zhong Wu; Mahboob U Rahman
Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
The Journal of rheumatology 2012;39(6):1185-91.
2011: Mark C Genovese; M Keiserman; C Legerton; G Leon; E Mysler; P Nash; E Nasonov; R Pappu; W Porawska; J A Simon-Campos; J Teng; R Valente; R Aranda; J Box; A Covarrubias; I Delaet; Patrick Durez; R Alten
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Arthritis and rheumatism 2011;63(10):2854-64.
2011: Mark C Genovese; N Kinnman; C Pena Rossi; G de La Bourdonnaye; P P Tak
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial.
Arthritis and rheumatism 2011;63(7):1793-803.
2011: Mark C Genovese; Stanley B Cohen; David Wofsy; Michael E Weinblatt; Gary S Firestein; Ernest Brahn; Vibeke Strand; Daniel G Baker; Sandra E Tong
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.
The Journal of rheumatology 2011;38(5):846-54.
2011: Michael E Weinblatt; Joan M Bathon; Scott W Baumgartner; Roy M Fleischmann; Joel M Kremer; Edward L Mancini; Richard W Martin; Grace S Park; Michael H Schiff; Mark C Genovese
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
Arthritis care & research 2011;63(3):373-82.
2011: Mark C Genovese; Arthur Kavanaugh; Michael E Weinblatt; Charles Peterfy; Julie DiCarlo; Michael L White; Maryann O'Brien; Elliott B Grossbard; Daniel B Magilavy
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Arthritis and rheumatism 2011;63(2):337-45.
2010: Mark C Genovese; F Van den Bosch; S A Roberson; S Bojin; I M Biagini; Peter Ryan; J Sloan-Lancaster
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
Arthritis and rheumatism 2010;62(4):929-39.
2009: Mark C Genovese; F C Breedveld; P Emery; S Cohen; Edward C Keystone; E L Matteson; Y Baptiste; A Chai; L Burke; W Reiss; M Sweetser; T M Shaw
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.
Annals of the rheumatic diseases 2009;68(12):1894-7.
2009: Mark C Genovese
Inhibition of p38: has the fat lady sung?
Arthritis and rheumatism 2009;60(2):317-20.
2009: Wolfgang Hueber; Beren H Tomooka; Franak Batliwalla; Wentian Li; Paul A Monach; Robert J Tibshirani; Ronald van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C Genovese; Lars Klareskog; Peter K Gregersen; William H Robinson
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
Arthritis research & therapy 2009;11(3):R76.
2008: Mark C Genovese; James D McKay; Evgeny L Nasonov; Eduardo F Mysler; Nilzio A da Silva; Emma Alecock; Thasia Woodworth; Juan J Gomez Reino
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Arthritis and rheumatism 2008;58(10):2968-80.
2008: Mark C Genovese; Jeffrey L Kaine; Mitchell B Lowenstein; José Del Giudice; Andrew Baldassare; Joy Schechtman; Edward Fudman; Michael Kohen; Sheila Gujrathi; Robert G Trapp; Nadera Sweiss; Greg Spaniolo; Wolfgang Dummer
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Arthritis and rheumatism 2008;58(9):2652-61.
2007: A L Rozelle; Mark C Genovese
Efficacy results from pivotal clinical trials with abatacept.
Clinical and experimental rheumatology 2007;25(5 Suppl 46):S30-4.
2007: Lorinda Chung; Mark C Genovese; David Fiorentino
A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Archives of dermatology 2007;143(6):763-7.
2007: Molly D Magnano; Eliza F Chakravarty; Corrie Broudy; Lorinda Chung; Ariella Kelman; Jennifer Hillygus; Mark C Genovese
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands.
The Journal of rheumatology 2007;34(6):1323-7.
2007: Wolfgang Hueber; Beren H Tomooka; XIAOYAN ZHAO; Brian A Kidd; Jan Wouter Drijfhout; James F Fries; Walther J van Venrooij; Allan L Metzger; Mark C Genovese; William H Robinson
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines.
Annals of the rheumatic diseases 2007;66(6):712-9.
2007: Mark C Genovese; Philip J Mease; Glen T D Thomson; Alan J Kivitz; Renee J Perdok; Mark A Weinberg; John Medich; Eric H Sasso
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
The Journal of rheumatology 2007;34(5):1040-50.
2006: Ricardo T Paniagua; Orr Sharpe; Peggy P Ho; Steven M Chan; Anna Chang; John P Higgins; Beren H Tomooka; Fiona M Thomas; Jason J Song; Stuart Goodman; David M Lee; Mark C Genovese; Paul J Utz; Lawrence Steinman; William H Robinson
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
The Journal of clinical investigation 2006;116(10):2633-42.
2006: Stanley B Cohen; Paul Emery; Maria W Greenwald; Maxime Dougados; Richard Furie; Mark C Genovese; Edward C Keystone; James E Loveless; Gerd R Burmester; Matthew W Cravets; Eva W Hessey; Timothy Shaw; Mark C Totoritis
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Arthritis and rheumatism 2006;54(9):2793-806.
2006: Michael H Schiff; Elaine B Yu; Michael E Weinblatt; Larry W Moreland; Mark C Genovese; Barbara A White; Amitabh Singh; Yun Chon; J Michael Woolley
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Drugs & aging 2006;23(2):167-78.
2005: Steven R Binder; Mark C Genovese; Joan T Merrill; Robert I Morris; Allan L Metzger
Computer-assisted pattern recognition of autoantibody results.
Clinical and diagnostic laboratory immunology 2005;12(12):1353-7.
2005: Mark C Genovese; Eliza F Chakravarty; David L Boyle; Zuhre Tutuncu; Christine M Thorburn; Merita Halilhodzic; Stewart Kroll; Jan Baughman; Stanford Stewart; Arthur Kavanaugh
A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
The Journal of rheumatology 2005;32(12):2345-50.
2005: Molly D Magnano; Mark C Genovese
Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.
Current rheumatology reports 2005;7(5):407-15.
2005: Wolfgang Hueber; Brian A Kidd; Beren H Tomooka; Byung J Lee; Bonnie Bruce; James F Fries; Grete Sønderstrup; Paul A Monach; Jan Wouter Drijfhout; Walther J van Venrooij; Paul J Utz; Mark C Genovese; William H Robinson
Antigen microarray profiling of autoantibodies in rheumatoid arthritis.
Arthritis and rheumatism 2005;52(9):2645-55.
2005: Mark C Genovese; Joan M Bathon; Roy Fleischmann; Larry W Moreland; Richard W Martin; James B Whitmore; Wayne Tsuji; Jonathan A Leff
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
The Journal of rheumatology 2005;32(7):1232-42.
2005: Mark C Genovese
Biologic therapies in clinical development for the treatment of rheumatoid arthritis.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2005;11(3 Suppl):S45-54.
2005: Eliza F Chakravarty; Iris Colón; Elizabeth S Langen; David A Nix; Yasser Y El-Sayed; Mark C Genovese; Maurice L Druzin
Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus.
American journal of obstetrics and gynecology 2005;192(6):1897-904.
2004: Molly D Magnano; William H Robinson; Mark C Genovese
Demyelination and inhibition of tumor necrosis factor (TNF).
Clinical and experimental rheumatology 2004;22(5 Suppl 35):S134-40.
2004: Karen E Hansen; Julie P Hildebrand; Mark C Genovese; John J Cush; Supen Patel; David A Cooley; Stanley B Cohen; Ronald E Gangnon; Michael H Schiff
The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
The Journal of rheumatology 2004;31(6):1098-102.
2004: Mark C Genovese; Joel M Kremer
Treatment of rheumatoid arthritis with etanercept.
Rheumatic diseases clinics of North America 2004;30(2):311-28, vi-vii.
2004: Eliza F Chakravarty; Mark C Genovese
Associations between rheumatoid arthritis and malignancy.
Rheumatic diseases clinics of North America 2004;30(2):271-84, vi.
2004: Paul J Utz; Mark C Genovese; William H Robinson
Unlocking the "PAD" lock on rheumatoid arthritis.
Annals of the rheumatic diseases 2004;63(4):330-2.
2003: Joan M Bathon; Mark C Genovese
The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate.
Clinical and experimental rheumatology 2003;21(5 Suppl 31):S195-7.
2002: Joel M Kremer; Mark C Genovese; Grant W Cannon; Jacques R Caldwell; John J Cush; Daniel E Furst; Michael Luggen; Edward C Keystone; Michael H Weisman; William M Bensen; Jeffrey L Kaine; Eric M Ruderman; Patricia Coleman; David L Curtis; Elliot J Kopp; Seth M Kantor; Jonathan Waltuck; Herbert B Lindsley; Joseph A Markenson; Vibeke Strand; Bruce Crawford; Indra Fernando; Karen Simpson; Joan M Bathon
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Annals of internal medicine 2002;137(9):726-33.
2002: Yasser Y El-Sayed; E J Lu; Mark C Genovese; R E Lambert; Usha Chitkara; Maurice L Druzin
Central nervous system lupus and pregnancy: 11-year experience at a single center.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2002;12(2):99-103.
2002: Mark C Genovese; Joan M Bathon; Richard W Martin; Roy Fleischmann; John Tesser; Michael H Schiff; Edward C Keystone; Mary Chester Wasko; Larry W Moreland; Arthur L Weaver; Joseph A Markenson; Grant W Cannon; George Spencer-Green; barbara finck
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Arthritis and rheumatism 2002;46(6):1443-50.
2002: Mark C Genovese; Zuzana Uhrin; Daniel A Bloch; John Oehlert; Richard K Sibley; Bryan Myers; Samuel Strober
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritis.
Arthritis and rheumatism 2002;46(4):1014-8.
2002: William H Robinson; Carla DiGennaro; Wolfgang Hueber; Brian B Haab; Makoto Kamachi; Erik J Dean; Sylvie Fournel; Derek Fong; Mark C Genovese; Henry Neuman de Vegvar; Karl Skriner; David L Hirschberg; Robert I Morris; Sylviane Muller; Ger J Pruijn; Walther J van Venrooij; Josef S Smolen; Patrick O Brown; Lawrence Steinman; Paul J Utz
Autoantigen microarrays for multiplex characterization of autoantibody responses.
Nature medicine 2002;8(3):295-301.
2002: Eric J Kunkel; Judie Boisvert; Kristine Murphy; Mark A Vierra; Mark C Genovese; Andrew J Wardlaw; Harry B Greenberg; Martin R Hodge; Lijun Wu; Eugene C Butcher; James J Campbell
Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes.
The American journal of pathology 2002;160(1):347-55.
2001: Chang H Kim; Lusijah S Rott; Eric J Kunkel; Mark C Genovese; David Andrew; Lijun Wu; Eugene C Butcher
Rules of chemokine receptor association with T cell polarization in vivo.
The Journal of clinical investigation 2001;108(9):1331-9.
2001: William H Robinson; Mark C Genovese; L W Moreland
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
Arthritis and rheumatism 2001;44(9):1977-83.
2001: Z Uhrin; B W Wang; Y Matsuda; Samuel Strober; Mark C Genovese
Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival.
Arthritis and rheumatism 2001;44(7):1525-8.
2001: Chang H Kim; Eric J Kunkel; Judie Boisvert; Brent Johnston; James J Campbell; Mark C Genovese; Harry B Greenberg; Eugene C Butcher
Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential.
The Journal of clinical investigation 2001;107(5):595-601.
2001: Mark C Genovese; J S Davis
Current management of rheumatoid arthritis.
Hospital practice (1995) 2001;36(2):21-6, 29-30, 35.
2001: James J Campbell; KE Murphy; Eric J Kunkel; Christopher E Brightling; Dulce Soler; Z Shen; Judie Boisvert; Harry B Greenberg; Mark A Vierra; Stuart Goodman; Mark C Genovese; Andrew J Wardlaw; Eugene C Butcher; Lijun Wu
CCR7 expression and memory T cell diversity in humans.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(2):877-84.
2000: Joan M Bathon; R W Martin; Roy Fleischmann; John Tesser; Michael H Schiff; E C Keystone; Mark C Genovese; Mary Chester Wasko; Larry W Moreland; Arthur L Weaver; Joseph A Markenson; barbara finck
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.
The New England journal of medicine 2000;343(22):1586-93.
2000: Junliang Pan; Eric J Kunkel; U Gosslar; Nicole H Lazarus; P Langdon; K Broadwell; Mark A Vierra; Mark C Genovese; Eugene C Butcher; Dulce Soler
A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(6):2943-9.
2000: Eric J Kunkel; James J Campbell; Guttorm Haraldsen; Junliang Pan; Judie Boisvert; Arthur I Roberts; Ellen C Ebert; Mark A Vierra; Stuart Goodman; Mark C Genovese; Andrew J Wardlaw; Harry B Greenberg; Christina M Parker; Eugene C Butcher; David Andrew; William W Agace
Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity.
The Journal of experimental medicine 2000;192(5):761-8.
1998: Mark C Genovese
Joint and soft-tissue injection. A useful adjuvant to systemic and local treatment.
Postgraduate medicine 1998;103(2):125-34.
1997: Mark C Genovese
Fever, rash, and arthritis in a woman with silicone gel breast implants.
The Western journal of medicine 1997;167(3):149-58.